Xing Sun

446 total citations
10 papers, 306 citations indexed

About

Xing Sun is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Xing Sun has authored 10 papers receiving a total of 306 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 3 papers in Molecular Biology and 2 papers in Pathology and Forensic Medicine. Recurrent topics in Xing Sun's work include CAR-T cell therapy research (2 papers), Histone Deacetylase Inhibitors Research (2 papers) and Statistical Methods in Clinical Trials (2 papers). Xing Sun is often cited by papers focused on CAR-T cell therapy research (2 papers), Histone Deacetylase Inhibitors Research (2 papers) and Statistical Methods in Clinical Trials (2 papers). Xing Sun collaborates with scholars based in United States, China and Canada. Xing Sun's co-authors include Gregory M. Lubiniecki, Anne S. Tsao, Kazuya Fukuoka, Quincy S. Chu, Paul Baas, Christian Manegold, Margaret Smith, Ruth Plummer, R. Öhman and Dean A. Fennell and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and British Journal of Haematology.

In The Last Decade

Xing Sun

9 papers receiving 301 citations

Peers

Xing Sun

MB

PRM

HEMAT

ONCOL

PFM

Selena Dixon United Kingdom

Rachael Brake United States

Steve McCune United States

Josh Sommer United States

Bharani Dharan United States

Luigi Cerbone Italy

Hiroshi Yoshibayashi Japan

Stephen Chanock United States

Etienne Suc France

Susan K. Roethke United States

Selena Dixon United Kingdom

Xing Sun

105 ×0.8

MB

159 ×1.4

PRM

81 ×1.2

HEMAT

70 ×1.1

ONCOL

11 ×0.5

PFM

Citations per year, relative to Xing Sun Xing Sun (= 1×) peers Selena Dixon

Countries citing papers authored by Xing Sun

Since Specialization

Citations

This map shows the geographic impact of Xing Sun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xing Sun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xing Sun more than expected).

Fields of papers citing papers by Xing Sun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xing Sun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xing Sun. The network helps show where Xing Sun may publish in the future.

Co-authorship network of co-authors of Xing Sun

This figure shows the co-authorship network connecting the top 25 collaborators of Xing Sun. A scholar is included among the top collaborators of Xing Sun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xing Sun. Xing Sun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Sun, Xing, et al.. (2021). Patient feedback identifies “Rheum” to improve clinic visit preparedness. Clinical Rheumatology. 41(1). 275–279.

2.

Tao, Rong, Lei Fan, Yongping Song, et al.. (2020). Sintilimab for Relapsed/Refractory Extranodal NK/T-Cell Lymphoma: A Multicenter, Single-Arm, Phase 2 Trial (ORIENT-4). SSRN Electronic Journal. 8 indexed citations

3.

Li, Jianyong, Rong Tao, Lei Fan, et al.. (2020). Sintilimab for relapsed/refractory (r/r) extranodal NK/T cell lymphoma (ENKTL): Extended follow-up on the multicenter, single-arm phase II trail (ORIENT-4).. Journal of Clinical Oncology. 38(15_suppl). 8050–8050. 11 indexed citations

4.

Xu, Jianming, Yingxin Li, Xing Sun, et al.. (2017). A phase I and pharmacokinetic study of afilbercept with FOLFIRI: comparison of Chinese and Caucasian populations. Investigational New Drugs. 35(4). 463–470. 2 indexed citations

5.

Krug, Lee M., Hedy L. Kindler, Hilary Calvert, et al.. (2015). Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. The Lancet Oncology. 16(4). 447–456. 143 indexed citations

6.

Kirschbaum, Mark, Ivana Gojo, Stuart L. Goldberg, et al.. (2014). A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome. British Journal of Haematology. 167(2). 185–193. 96 indexed citations

7.

Sun, Xing, et al.. (2013). A Review of Statistical Issues with Progression-Free Survival as an Interval-Censored Time-to-Event Endpoint. Journal of Biopharmaceutical Statistics. 23(5). 986–1003. 9 indexed citations

8.

Gao, Siyuan, Xue Han, Jihua Fu, et al.. (2012). Influence of chronic stress on the compositions of hepatic cholesterol and triglyceride in male Wistar rats fed a high fat diet. Hepatology Research. 42(7). 686–695. 6 indexed citations

9.

Sun, Xing & Cong Chen. (2010). Comparison of Finkelstein’s Method With the Conventional Approach for Interval-Censored Data Analysis. Statistics in Biopharmaceutical Research. 2(1). 97–108. 16 indexed citations

10.

Hansen, James E., et al.. (2008). Argument for changing criteria for bronchodilator responsiveness. Respiratory Medicine. 102(12). 1777–1783. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact